



Fax completed form to: (855) 840-1678

If this is an URGENT request, please call (800) 882-4462 (800.88.CIGNA)

# Uplizna (inebilizumab-cdon)

PHYSICIAN INFORMATION			PATIENT INFORMATION		
* Physician Name:			*Due to privacy regulations we will not be able to respond via fax with the outcome of our review unless all asterisked (*) items on this form are completed.*		
Specialty:	* DEA, NPI or TIN:				
Office Contact Person:			* Patient Name:		
Office Phone:			* Cigna ID:	* Date of Birth:	
Office Fax:			* Patient Street Address:		
Office Street Address:			City:	State:	Zip:
City:	State:	Zip:	Patient Phone:		
<b>Urgency:</b>					
<input type="checkbox"/> Standard <input type="checkbox"/> Urgent (In checking this box, I attest to the fact that applying the standard review time frame may seriously jeopardize the customer's life, health, or ability to regain maximum function)					
<b>Medication Requested:</b>			ICD10:		
<input type="checkbox"/> Uplizna 100mg/10ml vial					
Directions for use:	Dose:	Quantity:	Duration of therapy:		
<b>Where will this medication be obtained?</b>					
<input type="checkbox"/> Accredo Specialty Pharmacy** <input type="checkbox"/> Hospital Outpatient <input type="checkbox"/> Retail pharmacy <input type="checkbox"/> Other (please specify):			<input type="checkbox"/> Home Health / Home Infusion vendor <input type="checkbox"/> Physician's office stock (billing on a medical claim form) <b>**Cigna's nationally preferred specialty pharmacy</b>		
<i>**Medication orders can be placed with Accredo via E-prescribe - Accredo (1620 Century Center Pkwy, Memphis, TN 38134-8822   NCPDP 4436920), Fax 888.302.1028, or Verbal 866.759.1557</i>					
<b>Facility and/or doctor dispensing and administering medication:</b>					
Facility Name:		State:	Tax ID#:		
Address (City, State, Zip Code):					
<b>Where will this drug be administered?</b>					
<input type="checkbox"/> Patient's Home <input type="checkbox"/> Hospital Outpatient			<input type="checkbox"/> Physician's Office <input type="checkbox"/> Other (please specify):		
<b>NOTE: Per some Cigna plans, infusion of medication MUST occur in the least intensive, medically appropriate setting.</b>					
Is this patient a candidate for re-direction to an alternate setting (such as alternate infusion site, physician's office, home) with assistance of a Specialty Care Options Case Manager? <input type="checkbox"/> Yes <input type="checkbox"/> No (provide medical necessity rationale):					
Is the requested medication for a chronic or long-term condition for which the prescription medication may be necessary for the life of the patient? <input type="checkbox"/> Yes <input type="checkbox"/> No					
<b>Diagnosis:</b>					
<input type="checkbox"/> Neuromyelitis Optica Spectrum Disorder (NMOSD) <input type="checkbox"/> Other (Please specify):					
<b>Clinical Information:</b>					
Was the patient's diagnosis confirmed by blood serum test for anti-aquaporin-4 antibody positive disease? <span style="float: right;">Yes <input type="checkbox"/> No <input type="checkbox"/></span>					

Besides the drug being requested, other medications include: a Rituximab Product, Enspryng (satralizumab-mwge subcutaneous injection), or Soliris (eculizumab intravenous infusion), or Ultomiris (ravulizumab-cwyz intravenous infusion). Which of the following best describes your patient's situation?

- The patient is NOT taking any other drug at this time, nor will they in the future. The requested drug is the only drug the patient is/will be using.
- The patient is currently on another drug, but this drug will be stopped and the requested drug will be started
- The patient is currently on another drug, and the requested drug will be added. The patient may continue to take both drugs together.
- The patient is currently on BOTH the requested drug AND another drug.
- Other/Unknown

(if duplicate therapy or unknown) Please provide the rationale for concurrent use.

Is the requested medication being prescribed by (or in consultation with) a neurologist?

Yes  No

Is this a new start or currently receiving Uplizna? If patient has been taking samples, please pick "new start."

- new start
- Currently Receiving Uplizna

(if continued therapy) Is there documentation of a clinical benefit from the use of Uplizna? Note: Examples of clinical benefit include reduction in relapse rate, reduction in symptoms (e.g., pain, fatigue, motor function), and a slowing progression in symptoms.

Yes  No

(if no) Please provide support for continued use.

**Additional pertinent information** Please provide any additional pertinent clinical information, including: if the patient is currently on the requested drug (with dates of use) and how they have been receiving it (samples, out of pocket, etc.).

Attestation: I attest the information provided is true and accurate to the best of my knowledge. I understand that the Health Plan or insurer its designees may perform a routine audit and request the medical information necessary to verify the accuracy of the information reported on this form.

Prescriber Signature: \_\_\_\_\_

Date: \_\_\_\_\_

Save Time! Submit Online at: [www.covermy meds.com/main/prior-authorization-forms/cigna/](http://www.covermy meds.com/main/prior-authorization-forms/cigna/) or via SureScripts in your EHR.

*Our standard response time for prescription drug coverage requests is 5 business days. If your request is urgent, it is important that you call us to expedite the request. View our Prescription Drug List and Coverage Policies online at [cigna.com](http://cigna.com).*

v080124

"Cigna" is a registered service mark, and the "Tree of Life" logo is a service mark, of Cigna Intellectual Property, Inc., licensed for use by Cigna Corporation and its operating subsidiaries. All products and services are provided by or through such operating subsidiaries and not by Cigna Corporation. Such operating subsidiaries include, for example, Cigna Health and Life Insurance Company and Cigna Health Management, Inc. Address: Cigna Pharmacy Services, PO Box 42005, Phoenix AZ 85080-2005